Vita Life Sciences Limited

As of December 31, 2025, Vita Life Sciences Limited carries a market capitalization of 143.18M, placing it among publicly traded companies globally. Its enterprise value stands at 109.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Vita Life Sciences Limited has 55.50M shares outstanding.

As of December 31, 2025, Vita Life Sciences Limited trades at a trailing price-to-earnings ratio of 13.85. The price-to-sales ratio is 1.55, and the price-to-book ratio stands at 2.55.

As of December 31, 2025, Vita Life Sciences Limited trades at an EV/EBITDA multiple of 7.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 109.92M versus a market cap of 143.18M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Vita Life Sciences Limited maintains a current ratio of 2.72, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.26, indicating elevated leverage, while an interest coverage ratio of 42.70 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Vita Life Sciences Limited posted a return on equity (ROE) of 19.22, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.22, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.29 indicates how many times Vita Life Sciences Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Vita Life Sciences Limited recorded 4.00M in income tax expense. That works out to an effective tax rate of 27.75, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.43M, leaving 10.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Vita Life Sciences Limited's stock has gained approximately 17.15% over the past 52 weeks. The 50-day moving average sits at 2.76, while the 200-day moving average is 2.59.

Over the twelve months ended December 31, 2025, Vita Life Sciences Limited generated 93.27M in revenue and converted that into 10.44M in net income, yielding earnings per share of 0.18. EBITDA reached 15.07M, while operating income came in at 14.07M.

As of December 31, 2025, Vita Life Sciences Limited holds 35.56M in cash and equivalents against 2.39M in total debt, resulting in a net debt position of -35.56M. Total book value stands at 56.25M, with working capital of 41.68M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Vita Life Sciences Limited posted a gross margin of 61.15, reflecting its pricing power and cost economics. The operating margin of 15.08 and net profit margin of 11.19 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Vita Life Sciences Limited paid dividends of 0.11 per share. The dividend payout ratio of 58.36 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.35, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vita Life Sciences Limited shareholders.

As of December 31, 2025, Vita Life Sciences Limited has an Altman Z-Score of 5.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.